Cyclooxygenase 2: its regulation, role and impact in airway inflammation

Clinical and Experimental Allergy - Tập 46 Số 3 - Trang 397-410 - 2016
Nowshin N. Rumzhum1, Alaina J. Ammit1
1Faculty of Pharmacy, University of Sydney, Sydney NSW, Australia

Tóm tắt

SummaryCyclooxygenase 2 (COX‐2: official gene symbol – PTGS2) has long been regarded as playing a pivotal role in the pathogenesis of airway inflammation in respiratory diseases including asthma. COX‐2 can be rapidly and robustly expressed in response to a diverse range of pro‐inflammatory cytokines and mediators. Thus, increased levels of COX‐2 protein and prostanoid metabolites serve as key contributors to pathobiology in respiratory diseases typified by dysregulated inflammation. But COX‐2 products may not be all bad: prostanoids can exert anti‐inflammatory/bronchoprotective functions in airways in addition to their pro‐inflammatory actions. Herein, we outline COX‐2 regulation and review the diverse stimuli known to induce COX‐2 in the context of airway inflammation. We discuss some of the positive and negative effects that COX‐2/prostanoids can exert in in vitro and in vivo models of airway inflammation, and suggest that inhibiting COX‐2 expression to repress airway inflammation may be too blunt an approach; because although it might reduce the unwanted effects of COX‐2 activation, it may also negate the positive effects. Evidence suggests that prostanoids produced via COX‐2 upregulation show diverse actions (and herein we focus on prostaglandin E2 as a key example); these can be either beneficial or deleterious and their impact on respiratory disease can be dictated by local concentration and specific interaction with individual receptors. We propose that understanding the regulation of COX‐2 expression and associated receptor‐mediated functional outcomes may reveal number of critical steps amenable to pharmacological intervention. These may prove invaluable in our quest towards future development of novel anti‐inflammatory pharmacotherapeutic strategies for the treatment of airway diseases.

Từ khóa


Tài liệu tham khảo

10.1042/bj3020723

10.1016/j.plipres.2007.01.001

10.1042/BST0360543

10.1074/jbc.M300016200

10.1074/jbc.275.16.11750

10.1016/S1097-2765(03)00012-1

10.1074/jbc.M301481200

Erkinheimo TL, 2003, Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma, Cancer Res, 63, 7591

10.2353/ajpath.2009.080652

10.1093/nar/gki544

10.1261/rna.577707

10.1073/pnas.86.5.1657

10.1042/bj20031484

10.1084/jem.20030616

10.1073/pnas.0400148101

10.1074/jbc.M008461200

10.1038/onc.2008.97

10.1053/j.gastro.2004.06.022

10.1128/MCB.01275-12

10.1016/S0014-5793(98)01342-8

10.1074/jbc.274.1.264

10.1038/sj.neo.7900117

10.1074/jbc.M003224200

10.1128/MCB.21.3.771-780.2001

10.1073/pnas.0705917104

10.1371/journal.pone.0050935

10.1007/s10875-012-9834-5

10.1152/ajplung.00174.2014

10.1165/rcmb.2014-0129OC

10.1006/abbi.1993.1168

10.1016/S0021-9258(17)46835-9

10.1074/jbc.M114.632463

10.1074/jbc.273.12.6801

10.1074/jbc.274.46.32936

10.1073/pnas.0601805103

10.1074/jbc.M710137200

10.1074/jbc.M109.052415

10.5483/BMBRep.2009.42.9.552

10.1016/0014-5793(93)80109-8

10.1006/bbrc.2001.6071

10.1074/jbc.M608281200

10.1006/abbi.1999.1646

10.1074/jbc.M109145200

10.1007/s00109-007-0197-y

10.1074/jbc.M113.521799

10.1210/en.2011-1438

10.1002/jcb.22407

10.1016/0091-6749(92)90218-Q

10.1164/ajrccm/147.2.291

10.1164/ajrccm.154.4.8887608

10.1111/j.1476-5381.1994.tb17093.x

10.1038/sj.bjp.0700963

10.1038/sj.bjp.0701152

10.1046/j.1365-2222.1999.00573.x

10.1152/ajplung.00070.2002

10.1128/MCB.23.24.9233-9244.2003

10.1016/S0024-3205(96)00590-5

10.1006/bbrc.1997.7064

10.1016/S0014-5793(97)01362-8

10.1006/bbrc.1997.6586

10.1074/jbc.273.48.32312

10.1152/ajplung.1999.277.5.L943

10.1152/ajplung.2000.279.5.L932

10.1038/sj.bjp.0703431

10.1111/all.12449

10.1165/rcmb.2014-0443OC

10.1111/j.1476-5381.1995.tb13353.x

10.1111/all.12810

10.1371/journal.pone.0056058

10.1016/j.bbrc.2013.07.006

10.1172/JCI112782

10.1152/ajplung.1997.273.6.L1132

Pang L, 1998, Bradykinin stimulates IL‐8 production in cultured human airway smooth muscle cells: role of cyclooxygenase products, J Immunol, 161, 2509, 10.4049/jimmunol.161.5.2509

10.1016/S0014-5793(04)00064-X

10.1164/rccm.200506-850OC

10.1136/thx.2004.037473

10.1152/ajplung.00239.2003

10.1016/j.freeradbiomed.2009.10.047

10.1371/journal.pone.0054125

10.1038/sj.bjp.0701283

10.1096/fj.00-0742fje

10.1016/j.lfs.2007.02.008

10.1111/all.12489

10.1002/jcp.24795

10.4049/jimmunol.170.2.1043

10.1164/ajrccm.162.6.2003127

10.1152/ajplung.00416.2002

10.1164/ajrccm.153.1.8542168

10.1136/thorax.58.7.585

10.1111/j.1440-1843.2008.01365.x

10.1586/17476348.2015.992783

10.1164/ajrccm.155.2.9032211

10.1016/j.molimm.2011.01.007

10.1152/ajplung.1998.275.2.L322

10.1042/cs0840151

10.1165/ajrcmb.19.2.3025

10.1152/ajplung.1998.275.3.L491

10.1038/sj.bjp.0702193

10.1152/ajplung.2001.281.6.L1425

10.1016/S1569-9048(03)00146-0

10.1016/j.pupt.2012.05.007

10.1165/rcmb.2009-0126OC

10.1172/JCI25840

10.1172/JCI110207

10.1124/mol.62.5.1112

10.1124/mol.66.2.337

10.1159/000024452

10.1378/chest.117.3.684

10.1007/BF00562439

10.1016/j.pharmthera.2009.09.006

10.1007/s00408-009-9190-2

10.1016/j.coph.2011.06.005

10.1164/rccm.200903-0388OC

10.1183/09031936.00061614

10.1016/0003-9861(88)90147-6

Johnson PR, 1995, Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture, Am J Physiol, 269, L514

10.1038/sj.bjp.0702104

10.1038/sj.bjp.0702424

10.1165/rcmb.2002-0254OC

10.1165/rcmb.2007-0091OC

10.1016/S0140-6736(95)90409-3

10.1007/BF02112710

10.1136/bmj.4.5685.723

Smith AP, 1975, Effects of inhaled prostaglandins E1, E2, and F2alpha on the airway resistance of healthy and asthmatic man, Clin Sci Mol Med, 48, 421

10.1016/S0090-6980(75)80007-4

10.1164/ajrccm.149.5.8173753

10.1164/ajrccm.159.1.9804030

10.1016/S0014-2999(01)01520-5

10.1165/ajrcmb.23.6.4184

10.1152/ajplung.00046.2008

10.4049/jimmunol.1202462

10.1152/ajplung.2001.280.6.L1225

10.1096/fj.01-0256com

10.1016/j.febslet.2005.02.083

10.1016/j.iac.2012.11.006

10.1016/j.jaci.2014.08.020

10.1016/S1081-1206(10)60615-1

10.1164/ajrccm/143.5_Pt_1.1025

10.1164/ajrccm.153.2.8564100

10.1155/2012/789232

10.1124/mol.62.2.250

10.1074/jbc.M507045200

10.1038/sj.bjp.0706664

10.4049/jimmunol.181.10.7273

10.1164/ajrccm.160.1.9808048

10.1111/j.1398-9995.2010.02514.x

10.1164/ajrccm.153.2.8564099

10.4049/jimmunol.0902835

10.1073/pnas.1313185110

10.4049/jimmunol.1402959

10.4049/jimmunol.1500905

10.1016/j.jaci.2014.07.031

10.1016/j.jaci.2012.02.007

10.1165/rcmb.2014-0486OC

10.1016/j.jaci.2013.10.057

10.1016/j.jaip.2015.03.001

10.1136/thx.2010.158568

10.1111/j.1476-5381.2012.02088.x

10.1136/thoraxjnl-2014-206592

10.1111/cea.12542

10.1146/annurev.pharmtox.38.1.97

Thông tin
Thông tin xuất bản

Clinical and Experimental Allergy

Tập 46 Số 3

397-410

Thông tin tác giả